Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Screening for prostate cancer: an update.

Shariat SF, Scardino PT, Lilja H.

Can J Urol. 2008 Dec;15(6):4363-74. Review.

2.

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.

Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H.

J Urol. 2003 Oct;170(4 Pt 1):1169-74.

PMID:
14501718
3.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.

4.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.

PMID:
12384160
5.

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

Vickers AJ, Ulmert D, Serio AM, Björk T, Scardino PT, Eastham JA, Berglund G, Lilja H.

Int J Cancer. 2007 Nov 15;121(10):2212-7.

7.

Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).

Martin BJ, Finlay JA, Sterling K, Ward M, Lifsey D, Mercante D, Jainto JM, Martin L, Rayford W.

Prostate Cancer Prostatic Dis. 2004;7(2):132-7.

PMID:
15007379
8.
9.

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.

Hugosson J, Aus G, Bergdahl S, Fernlund P, Frösing R, Lodding P, Pihl CG, Lilja H.

BJU Int. 2003 Dec;92 Suppl 2:39-43.

10.

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.

PMID:
21482022
11.

Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.

Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.

Eur Urol. 2009 Mar;55(3):563-74. doi: 10.1016/j.eururo.2008.11.040. Epub 2008 Nov 29. Review.

PMID:
19058905
12.

Percent free PSA as an additional measure in a prostate cancer screen.

Miele ME.

Clin Lab Sci. 2001 Spring;14(2):102-7.

PMID:
15625982
13.

Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.

Chun FK, Perrotte P, Briganti A, Benayoun S, Lebeau T, Ramirez A, Lewinshtein DJ, Valiquette L, Guay JP, Karakiewicz PI.

BJU Int. 2006 Jul;98(1):50-3.

14.
15.
17.

The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen.

Herrmann W, Stöckle M, Sand-Hill M, Hübner U, Herrmann M, Obeid R, Wullich B, Loch T, Geisel J.

Clin Chem Lab Med. 2004;42(9):1051-7.

PMID:
15497472
18.

Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.

Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lümmen G, Tscholl R.

Urology. 2000 Apr;55(4):481-5.

PMID:
10736487
19.

Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.

Prostate. 2005 Aug 1;64(3):240-5.

PMID:
15712213
20.

Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?

Lippi G, Montagnana M, Guidi GC, Plebani M.

Ann Med. 2009;41(7):480-9. doi: 10.1080/07853890903156468. Review.

PMID:
19657768

Supplemental Content

Support Center